Evaluation of the combination of brentuximab vedotin and chemotherapy in peripheral CD30 + T lymphomas: controlled, randomized, double-blind trial

被引：0
|
作者：
Charlotte, Berthoux
Laure, Farnault
Geoffroy, Venton
机构：
来源：
HEMATOLOGIE | 2019年 / 25卷 / 02期
关键词：
D O I：
10.1684/hma.2019.1459
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：65 / 65
页数：1
相关论文
共 50 条
  • [21] Response to Brentuximab Vedotin by CD30 Expression: Results From Five Trials in PTCL, CTCL, and B-Cell Lymphomas
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 11 - 13
  • [22] Frontline Treatment of CD30+Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up
    Horwitz, Steven M.
    Shustov, Andrei R.
    Forero-Torres, Andres
    Bartlett, Nancy L.
    Advani, Ranjana
    Pro, Barbara
    Chen, Robert
    Davies, Andrew J.
    Illidge, Tim
    Huebner, Dirk
    Kennedy, Dana A.
    Fanale, Michelle A.
    BLOOD, 2015, 126 (23)
  • [23] Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas
    Ribereau-Gayon, Emmanuel
    Donzel, Marie
    Pham, Felix
    Romain-Scelle, Nicolas
    Perier-Muzet, Marie
    Balme, Brigitte
    Traverse-Glehen, Alexandra
    Ghesquieres, Herve
    Dalle, Stephane
    LEUKEMIA & LYMPHOMA, 2023, 64 (08) : 1424 - 1432
  • [24] Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas
    Fanale, Michelle A.
    Horwitz, Steven M.
    Forero-Torres, Andres
    Bartlett, Nancy L.
    Advani, Ranjana H.
    Pro, Barbara
    Chen, Robert W.
    Davies, Andrew J.
    Illidge, Tim
    Uttarwar, Mayur
    Huebner, Dirk
    Ren, Hong
    Shustov, Andrei R.
    BLOOD, 2016, 128 (22)
  • [25] Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression
    Saintes, C.
    Saint-Jean, M.
    Renaut, J. J.
    Dreno, B.
    Quereux, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (03) : 819 - 821
  • [26] The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
    Horwitz, S.
    O'Connor, O. A.
    Pro, B.
    Trumper, L.
    Iyer, S.
    Advani, R.
    Bartlett, N. L.
    Christensen, J. H.
    Morschhauser, F.
    Domingo-Domenech, E.
    Rossi, G.
    Kim, W. S.
    Feldman, T.
    Menne, T.
    Belada, D.
    Illes, A.
    Tobinai, K.
    Tsukasaki, K.
    Yeh, S-P
    Shustov, A.
    Huettmann, A.
    Savage, K. J.
    Yuen, S.
    Zinzani, P. L.
    Miao, H.
    Bunn, V
    Fenton, K.
    Fanale, M.
    Puhlmann, M.
    Illidge, T.
    ANNALS OF ONCOLOGY, 2022, 33 (03) : 288 - 298
  • [27] Applicability of Press Needles to a Double-blind Trial A Randomized, Double-blind, Placebo-controlled Trial
    Miyazaki, Shougo
    Hagihara, Akihito
    Kanda, Ryo
    Mukaino, Yoshito
    Nobutomo, Koichi
    CLINICAL JOURNAL OF PAIN, 2009, 25 (05): : 438 - 444
  • [28] Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas.
    Jagadeesh, Deepa
    Horwitz, Steven M.
    Bartlett, Nancy L.
    Advani, Ranjana H.
    Jacobsen, Eric D.
    Duvic, Madeleine
    Gautam, Ashish
    Rao, Shangbang
    Onsum, Matthew
    Fanale, Michelle
    Kim, Youn H.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Combination of Acupuncture and Fluoxetine for Depression: A Randomized, Double-Blind, Sham-Controlled Trial
    Zhang, Wen-Jing
    Yang, Xin-Bo
    Zhong, Bao-Liang
    JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2009, 15 (08) : 837 - 844
  • [30] Successful Treatment of an Aggressive Adult T-cell Leukemia/Lymphoma with Strong CD30 Expression Using Brentuximab Vedotin as Combination and Maintenance Therapy
    Baba, Yuta
    Sakai, Hirotaka
    Kabasawa, Nobuyuki
    Harada, Hiroshi
    INTERNAL MEDICINE, 2023, 62 (03) : 613 - 616
12345